| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics, Inc. | 1.92B | 39.81 | 511.70 | 31.18% | -33.24% | 3.91% | 0.14 | |
| GNFTGenfit S.A. | 313.52M | 6.27 | 209 | 134.56% | -14.12% | -31.42% | 4.54% | 0.90 |
| GYREGyre Therapeutics, Inc. | 741.77M | 7.70 | 154 | -6.78% | 6.2% | 4.84% | 0.02 | |
| TVRDTvardi Therapeutics, Inc. | 42.31M | 4.51 | -0.10 | -65.96% | -317.54% | -63.46% | ||
| UNCYUnicycive Therapeutics, Inc. | 134.75M | 6.27 | -1.12 | -100% | -89.15% | 0.10 | ||
| GLTOGalecto, Inc. | 38.32M | 23.95 | -1.29 | -237.68% | 0.00 | |||
| IVAInventiva S.A. | 1.17B | 6.12 | -1.73 | -47.37% | -13.75% | |||
| AKBAAkebia Therapeutics, Inc. | 355.59M | 1.34 | -4.06 | -17.7% | -7.07% | -38.24% |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 180.13M |
| Revenue Growth % | - | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 0 | 156 | 77K | 96K | 112K | 471K | 0 | 0 | 527K | 6.23M |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - | 0.03% |
| Gross Profit | 0 | -156 | -77K | -96K | -112K | -471K | 0 | 0 | -527K | 173.9M |
| Gross Margin % | - | - | - | - | - | - | - | - | - | 0.97% |
| Gross Profit Growth % | 1% | - | -492.59% | -0.25% | -0.17% | -3.21% | 1% | - | - | 330.98% |
| Operating Expenses | 3.17M | 24.98M | 31.81M | 40.36M | 94.86M | 205.85M | 242.48M | 293.57M | 379.97M | 671.77M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - | 3.73% |
| Selling, General & Admin | 13.39M | 9.29M | 7.67M | 14.97M | 22.65M | 21.86M | 37.32M | 48.13M | 108.15M | 435.06M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - | 2.42% |
| Research & Development | 54.22M | 15.93M | 24.39M | 25.39M | 72.32M | 184.81M | 205.16M | 245.44M | 271.82M | 236.72M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - | 1.31% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -3.17M | -24.98M | -31.89M | -40.46M | -94.97M | -206.32M | -242.48M | -293.57M | -380.5M | -497.88M |
| Operating Margin % | - | - | - | - | - | - | - | - | - | -2.76% |
| Operating Income Growth % | 0.96% | -6.88% | -0.28% | -0.27% | -1.35% | -1.17% | -0.18% | -0.21% | -0.3% | -0.31% |
| EBITDA | -3.17M | -24.98M | -31.81M | -40.36M | -94.86M | -205.85M | -242.08M | -293.1M | -379.97M | -496.78M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - | -2.76% |
| EBITDA Growth % | 0.96% | -6.88% | -0.27% | -0.27% | -1.35% | -1.17% | -0.18% | -0.21% | -0.3% | -0.31% |
| D&A (Non-Cash Add-back) | 2.58K | 156 | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 1.1M |
| EBIT | -3.23M | -25.18M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -291.39M | -360.92M | -451.22M |
| Net Interest Income | -3.61M | -1.16M | 558K | 7.67M | 11.02M | 4.33M | 363K | -1.78M | 6.87M | 31.98M |
| Interest Income | 0 | 48.3K | 558K | 7.67M | 11.02M | 4.33M | 363K | 2.19M | 19.58M | 46.65M |
| Interest Expense | 1.06M | 1.16M | 0 | 0 | 0 | 0 | 0 | 3.96M | 12.71M | 14.67M |
| Other Income/Expense | -3.67M | -1.41M | 732K | 7.64M | 11.02M | 4.08M | 636K | -1.78M | 6.87M | 31.98M |
| Pretax Income | -68.67M | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - | -2.59% |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 0.1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -6.84M | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M |
| Net Margin % | - | - | - | - | - | - | - | - | - | -2.59% |
| Net Income Growth % | 0.92% | -2.86% | -0.18% | -0.05% | -1.56% | -1.41% | -0.2% | -0.22% | -0.27% | -0.25% |
| Net Income (Continuing) | -6.84M | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -401.56 | -5.07 | -2.54 | -2.22 | -4.73 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 |
| EPS Growth % | -12.11% | 0.99% | 0.5% | 0.13% | -1.13% | -1.77% | -0.12% | -0.18% | -0.16% | -0.1% |
| EPS (Basic) | -401.56 | -5.07 | -2.54 | -2.22 | -4.73 | -13.09 | -14.63 | -17.23 | -19.99 | -21.90 |
| Diluted Shares Outstanding | 171.01K | 5.21M | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M |
| Basic Shares Outstanding | 171.01K | 5.21M | 12.24M | 14.8M | 15.39M | 15.45M | 16.54M | 17.14M | 18.69M | 21.27M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 363.58K | 41.21M | 192.01M | 485.2M | 440.2M | 285.16M | 271.68M | 361.37M | 637.28M | 1.03B |
| Cash & Short-Term Investments | 66.57M | 40.5M | 191.53M | 483.72M | 439.05M | 284.15M | 270.35M | 358.77M | 634.13M | 926.25M |
| Cash Only | 34.97M | 40.5M | 148.63M | 57.38M | 46.7M | 54M | 36.27M | 331.55M | 99.92M | 100.02M |
| Short-Term Investments | 31.61M | 0 | 42.9M | 426.34M | 392.35M | 230.15M | 234.08M | 27.23M | 534.22M | 826.23M |
| Accounts Receivable | 7.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 53.82M |
| Days Sales Outstanding | - | - | - | - | - | - | - | - | - | 109.06 |
| Inventory | -7.33K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 34.07M |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | 1.99K |
| Other Current Assets | 0 | 0 | 485K | 1.48M | 1.15M | 0 | 0 | 2.6M | 3.15M | 18.79M |
| Total Non-Current Assets | 420K | 3K | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 9.32M |
| Property, Plant & Equipment | 420K | 2.95K | 301K | 227K | 1.86M | 1.83M | 1.65M | 1.2M | 3.27M | 4.59M |
| Fixed Asset Turnover | - | - | - | - | - | - | - | - | - | 39.24x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.73M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Assets | 68.19M | 41.21M | 192.31M | 485.43M | 442.06M | 287M | 273.33M | 362.57M | 640.55M | 1.04B |
| Asset Turnover | - | - | - | - | - | - | - | - | - | 0.17x |
| Asset Growth % | -0.32% | -0.4% | 3.67% | 1.52% | -0.09% | -0.35% | -0.05% | 0.33% | 0.77% | 0.63% |
| Total Current Liabilities | 49.28M | 4.8M | 10.05M | 8.44M | 25.13M | 46.56M | 76.84M | 115.89M | 118.55M | 169.28M |
| Accounts Payable | 102.29K | 762K | 1.93M | 2.49M | 1.18M | 1.02M | 21.38M | 23.83M | 28.04M | 43.6M |
| Days Payables Outstanding | - | 1000K | 9.14K | 9.46K | 3.84K | 788.12 | - | - | 19.42K | 2.55K |
| Short-Term Debt | 49.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | -43K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 43K | 0 | 0 | 1.8M | 2.78M | 4.69M | 6.77M | 14.86M | 17.03M | 34.96M |
| Current Ratio | 0.01x | 8.58x | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 6.10x |
| Quick Ratio | 0.01x | 8.58x | 19.10x | 57.46x | 17.52x | 6.13x | 3.54x | 3.12x | 5.38x | 5.90x |
| Cash Conversion Cycle | - | - | - | - | - | - | - | - | - | -449.07 |
| Total Non-Current Liabilities | 0 | 0 | 0 | 0 | 361K | 468K | 387K | 49.29M | 116.67M | 118.59M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 49.29M | 115.48M | 117.57M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 361K | 468K | 387K | 0 | 1.19M | 1.02M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Liabilities | 17.79M | 4.8M | 10.05M | 8.44M | 25.49M | 47.02M | 77.22M | 165.18M | 235.21M | 287.86M |
| Total Debt | 4.65M | 0 | 0 | 0 | 676K | 786K | 797K | 49.89M | 117.19M | 119.57M |
| Net Debt | -30.32M | -40.5M | -191.53M | -483.72M | -46.02M | -53.22M | -35.47M | -281.66M | 17.28M | 19.55M |
| Debt / Equity | 0.09x | - | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -2.99x | -21.46x | - | - | - | - | - | -74.06x | -29.93x | -33.94x |
| Total Equity | 50.41M | 36.41M | 182.26M | 476.98M | 416.56M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M |
| Equity Growth % | -0.23% | -0.28% | 4.01% | 1.62% | -0.13% | -0.42% | -0.18% | 0.01% | 1.05% | 0.86% |
| Book Value per Share | 294.76 | 7.00 | 14.88 | 32.24 | 27.06 | 15.54 | 11.86 | 11.52 | 21.69 | 35.46 |
| Total Shareholders' Equity | 50.41M | 36.41M | 182.26M | 476.98M | 416.56M | 239.97M | 196.11M | 197.39M | 405.33M | 754.38M |
| Common Stock | 14K | 1.2K | 1K | 2K | 2K | 2K | 2K | 2K | 2K | 2K |
| Retained Earnings | -706.24M | -75.31M | -106.46M | -139.27M | -223.22M | -425.46M | -667.31M | -962.66M | -1.34B | -1.8B |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | 4K | 25.4K | -31K | -319K | 216K | 47K | -80K | -32K | 468K | 468K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -71.44M | -17.61M | -22.32M | -25.51M | -41.62M | -157.56M | -183.92M | -224.86M | -324.23M | -455.57M |
| Operating CF Margin % | - | - | - | - | - | - | - | - | - | -2.53% |
| Operating CF Growth % | 0.09% | 0.75% | -0.27% | -0.14% | -0.63% | -2.79% | -0.17% | -0.22% | -0.44% | -0.41% |
| Net Income | -68.67M | -26.39M | -31.15M | -32.81M | -83.95M | -202.24M | -241.85M | -295.35M | -373.63M | -465.89M |
| Depreciation & Amortization | 662K | 156 | 77K | 96K | 112K | 471K | 405K | 467K | 527K | 696K |
| Stock-Based Compensation | 4.3M | 8.68M | 3.25M | 13.49M | 22.76M | 20.73M | 26.87M | 31.63M | 49.73M | 79.88M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | -21.83M | -7.32M | 0 | 0 | 0 |
| Other Non-Cash Items | 3.48M | 1.21M | 2.49M | 13.12M | 0 | 21.83M | 7.32M | 797K | 2.41M | 2.09M |
| Working Capital Changes | -7.74M | -1.11M | 5.51M | -6.28M | 19.45M | 23.48M | 30.65M | 37.6M | -3.28M | -72.34M |
| Change in Receivables | 38.82K | 7.33M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -53.82M |
| Change in Inventory | 0 | -44.72M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -34.07M |
| Change in Payables | -1.84M | -128.06K | 917K | 558K | -1.31M | -161K | 20.36M | 2.45M | 4.21M | 15.56M |
| Cash from Investing | 20M | 21.99M | -22.01M | -380.08M | 30.71M | 159.78M | -5.05M | 206.69M | -502.52M | -274.39M |
| Capital Expenditures | -58K | -3.08K | -125K | -22K | -172K | -334K | -209K | -217K | -1.48M | -1.46M |
| CapEx % of Revenue | - | - | - | - | - | - | - | - | - | 0.01% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 780.01K | -21.88K | 3.67M | 0 | -1.92M | -787K | 3K | 0 | 19.09M |
| Cash from Financing | 40.39M | 14.45M | 173.81M | 314.33M | 235K | 5.09M | 171.24M | 313.45M | 595.12M | 735.06M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 0 | -82 | 0 | 2.51M | 235K | 667K | 1.03M | 8.07M | 269.93M | 337.57M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -71.5M | -17.61M | -22.44M | -25.53M | -41.8M | -157.9M | -184.13M | -225.07M | -325.71M | -457.03M |
| FCF Margin % | - | - | - | - | - | - | - | - | - | -2.54% |
| FCF Growth % | 0.1% | 0.75% | -0.27% | -0.14% | -0.64% | -2.78% | -0.17% | -0.22% | -0.45% | -0.4% |
| FCF per Share | -418.11 | -3.38 | -1.83 | -1.73 | -2.71 | -10.22 | -11.14 | -13.13 | -17.43 | -21.48 |
| FCF Conversion (FCF/Net Income) | 10.44x | 0.67x | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -11.85% | -60.79% | -28.49% | -9.95% | -18.79% | -61.61% | -110.92% | -150.12% | -123.98% | -80.35% |
| Return on Invested Capital (ROIC) | -8.96% | -234.17% | -161.9% | -13.39% | -18.03% | -55.53% | -104.7% | -576.64% | -168.69% | -62.41% |
| Gross Margin | - | - | - | - | - | - | - | - | - | 96.54% |
| Net Margin | - | - | - | - | - | - | - | - | - | -258.64% |
| Debt / Equity | 0.09x | - | - | - | 0.00x | 0.00x | 0.00x | 0.25x | 0.29x | 0.16x |
| Interest Coverage | -2.99x | -21.46x | - | - | - | - | - | -74.06x | -29.93x | -33.94x |
| FCF Conversion | 10.44x | 0.67x | 0.72x | 0.78x | 0.50x | 0.78x | 0.76x | 0.76x | 0.87x | 0.98x |
Madrigal Pharmaceuticals, Inc. (MDGL) reported $740.6M in revenue for fiscal year 2024. This represents a 9666% increase from $7.6M in 2011.
Madrigal Pharmaceuticals, Inc. (MDGL) grew revenue by 0.0% over the past year. Growth has been modest.
Madrigal Pharmaceuticals, Inc. (MDGL) reported a net loss of $289.1M for fiscal year 2024.
Madrigal Pharmaceuticals, Inc. (MDGL) has a return on equity (ROE) of -80.3%. Negative ROE indicates the company is unprofitable.
Madrigal Pharmaceuticals, Inc. (MDGL) had negative free cash flow of $161.6M in fiscal year 2024, likely due to heavy capital investments.